Compare TOWN & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOWN | PTGX |
|---|---|---|
| Founded | 1998 | 2006 |
| Country | United States | United States |
| Employees | 1251 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 5.2B |
| IPO Year | N/A | 2016 |
| Metric | TOWN | PTGX |
|---|---|---|
| Price | $34.45 | $102.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $106.67 |
| AVG Volume (30 Days) | 465.2K | ★ 855.2K |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.19% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.63 | $867.86 |
| Revenue Next Year | $5.18 | N/A |
| P/E Ratio | $16.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.43 | $39.60 |
| 52 Week High | $37.86 | $107.84 |
| Indicator | TOWN | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 59.36 | 59.27 |
| Support Level | $32.10 | $76.63 |
| Resistance Level | $34.90 | N/A |
| Average True Range (ATR) | 0.62 | 4.75 |
| MACD | 0.24 | -0.03 |
| Stochastic Oscillator | 95.04 | 68.48 |
Towne Bank is a financial services company serving individuals, commercial enterprises and professionals, offering retail and commercial banking services in Virginia and North Carolina. The company has four reportable segments: Banking, which provides loan and deposit services, commercial mortgage brokerage, and investment and asset management services; Mortgage, which originates mortgage loans principally sold in the secondary market through purchase commitments from investors; Resort Vacation Management, which provides residential resort property management services; and Insurance, which provides property, casualty, life and health insurance solutions for businesses, individuals and community organizations through a variety of carriers.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.